When Scott Kelly said "it is rare for a company with 2 BTDs to not be acquired"...that isn't the goal for CYDY is it? We've got too many potential indications to want to sell to BP in my opinion.

Also, really anticipating the CD17 trial starting. I think that's our quickest path to approval/revenue. Am I off on thinking that?